Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events

scientific article published on July 2000

Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S11883-000-0068-2
P698PubMed publication ID11122763

P2093author name stringMuhlestein JB
P2860cites workPrediction of Coronary Heart Disease Using Risk Factor CategoriesQ22241923
Association between dental health and acute myocardial infarctionQ24675367
The pathogenesis of atherosclerosis: a perspective for the 1990sQ29547827
The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniaeQ33843538
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.Q37060579
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC studyQ37875542
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS StudyQ37878753
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with ChlamydQ37878769
Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarctionQ37878896
Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertensionQ37879204
Animal models for Chlamydia pneumoniae infectionQ37879491
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit modelQ37881464
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study GroupQ37882250
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarctionQ37882420
Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstructionQ37882562
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimenQ37882581
Murine models of Chlamydia pneumoniae infection and atherosclerosisQ37883205
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study GroupQ37883953
Association of chlamydial infection with cerebrovascular diseaseQ37884018
Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular diseaseQ37884972
Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in FinlandQ37885075
Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery diseaseQ37887196
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stainQ37890285
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaquesQ37892518
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.Q37896793
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarctionQ37899465
Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo anginaQ39817564
Relation of Helicobacter pylori infection and coronary heart diseaseQ41333642
New insights into the pathogenesis and prevention of acute coronary syndromesQ41531482
Chlamydia pneumoniae and acute arterial thrombotic diseaseQ43432114
Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.Q52306854
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphologyQ72708405
The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatmentQ73071011
Anti-inflammatory activity of macrolides: a new therapeutic potential?Q74525799
P433issue4
P921main subjectcoronary artery diseaseQ844935
P304page(s)336-341
P577publication date2000-07-01
P1433published inCurrent Atherosclerosis ReportsQ20821076
P1476titleAntibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events
P478volume2

Search more.